Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
Aged
Alzheimer Disease
/ cerebrospinal fluid
Axons
/ pathology
Biomarkers
/ cerebrospinal fluid
Case-Control Studies
Chitinase-3-Like Protein 1
/ cerebrospinal fluid
Creutzfeldt-Jakob Syndrome
/ cerebrospinal fluid
Female
Frontotemporal Dementia
/ cerebrospinal fluid
Humans
Inflammation
Male
Middle Aged
Mutation
Neurofilament Proteins
/ cerebrospinal fluid
Neurogranin
/ cerebrospinal fluid
14-3-3
AT(N) system
Alzheimer's disease
Biomarker
Cerebrospinal fluid
Creutzfeldt-Jakob disease
Frontotemporal dementia
MCI due to AD
Mutation carriers
Neu rofilament light
Neurogranin
Preclinical AD
YKL-40
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
2
11
2019
medline:
28
10
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
Synaptic damage, axonal neurodegeneration, and neuroinflammation are common features in Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD). Unicentric cohort of 353 participants included healthy control (HC) subjects, AD continuum stages, genetic AD and FTD, and FTD and CJD. We measured cerebrospinal fluid neurofilament light (NF-L), neurogranin (Ng), 14-3-3, and YKL-40 proteins. Biomarkers showed differences in HC subjects versus AD, FTD, and CJD. Disease groups differed between them except AD versus FTD for YKL-40. Only NF-L differed between all stages within the AD continuum. AD and FTD symptomatic mutation carriers presented differences with respect to HC subjects. Applying the AT(N) system, 96% subjects were positive for neurodegeneration if 14-3-3 was used, 94% if NF-L was used, 62% if Ng was used, and 53% if YKL-40 was used. Biomarkers of synapse and neurodegeneration differentiate HC subjects from neurodegenerative dementias and between AD, FTD, and CJD. NF-L and 14-3-3 performed similar to total tau when AT(N) system was applied.
Identifiants
pubmed: 31668967
pii: S1552-5260(19)35369-5
doi: 10.1016/j.jalz.2019.09.001
doi:
Substances chimiques
Biomarkers
0
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
Neurofilament Proteins
0
neurofilament protein L
0
Neurogranin
132654-77-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-272Subventions
Organisme : Innovative Medicines Initiative Joint Undertaking
ID : 115568
Pays : International
Informations de copyright
© 2019 the Alzheimer's Association.
Références
Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis. 2018;62:1125-1140.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292-323.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
Jack Jr. DA, Bennett CR, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562.
Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38-48.
Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K, et al. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimers Dement. 2016;12:577-589.
Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, Polischi B, Oppi F, Poda R, et al. Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study. J Alzheimers Dis. 2018;66:551-563.
Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003;987:25-31.
Landqvist Waldö M, Frizell Santillo A, Passant U, Zetterberg H, Rosengren L, Nilsson C, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol. 2013;13:1-8.
Scherling CS, Hall T, Berisha F, Klepac K, Coppola G, Kramer JH, et al. CSF neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116-126.
Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3:623-636.
Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:505-512.
Zerr I, Schmitz M, Karch A, Villar-Piqué A, Kanata E, Golanska E, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018;14:751-763.
Illán-Gala I, Alcolea D, Montal V, Dols-Icardo O, Muñoz L, de Luna N, et al. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:e1619-e1628.
Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54:1960-1964.
Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83:1945-1953.
Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010;1362:13-22.
Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2015;11:1180-1190.
Tarawneh R, D’Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 2016;73:561-571.
Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829-835.
Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363-376.
Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Ann Clin Transl Neurol. 2016;3:12-20.
Foote M, Zhou Y. 14-3-3 Proteins in neurological disorders. Int J Biochem Mol Biol. 2012;3:152-164.
Llorens F, Karch A, Golanska E, Schmitz M, Lange P, Sikorska B, et al. Cerebrospinal fluid biomarker-based diagnosis of sporadic Creutzfeldt-Jakob disease: a validation study for previously established cutoffs. Dement Geriatr Cogn Disord. 2017;43:71-80.
Humpel C, Benke T. Cerebrospinal fluid levels of 14-3-3 gamma: what does it tell us about sporadic Creutzfeldt-Jakob disease?. Pharmacology. 2017;100:243-245.
Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology. 2001;56:1528-1533.
Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J Alzheimers Dis. 2014;42:901-908.
Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12:1-21.
Alcolea D, Irwin DJ, Illán-Gala I, Muñoz L, Clarimón J, Mcmillan T, et al. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. J Neurol Neurosurg Psychiatry. 2019;90:180-186.
Mckhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006-1014.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-2477.
Fortea J, Lladó A, Clarimón J, Lleó A, Oliva R, Peri J, et al. PICOGEN: experiencia de 5 años de un programa de asesoramiento genético en demencia. Neurologia. 2011;26:143-149.
Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, et al. Neurofilament ELISA validation. J Immunol Methods. 2010;352:23-31.
Schmitz M, Ebert E, Stoeck K, Karch A, Collins S, Calero M, et al. Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic. Mol Neurobiol. 2016;53:2189-2199.
Gaetani L, Höglund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10:1-13.
Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, Van Der Flier WM, et al. Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease: an assay comparison study. Clin Chem. 2018;64:927-937.
Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer's disease continuum. J Neuroinflammation. 2019;16:1-13.
Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9:251-261.
McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002;17:646-649.
Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med. 2016;8:1184-1196.
Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ 1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement. 2018;14:492-501.
Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR, et al. Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework. Alzheimers Dement. 2018;14:532-534.
Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25:277-283.